BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Atopic Dermatitis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Atopic Dermatitis\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06395948-1285@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Zumilokibart: Phase 2 readout est. (NCT06395948)
DESCRIPTION:Zumilokibart\, phase 2\, Atopic Dermatitis.\nStudy: A Study Eva
 luating APG777 in Atopic Dermatitis\nEstimated primary completion: Novembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zumilokibart#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0639
 5948
URL:https://assetmemo.bio/drug/zumilokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389136-12@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06389136)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic
  Dermatitis and Inadequate Response to Dupilumab\nEstimated primary comple
 tion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 upadacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06389136
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389136-1356@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06389136)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Atopic Dermatitis.\nStudy: A S
 tudy of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic 
 Dermatitis and Inadequate Response to Dupilumab\nEstimated primary complet
 ion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 upilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06389136
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06775860-1392@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Soficitinib (ICP-332): Phase 3 readout est. (NCT06775860)
DESCRIPTION:Soficitinib (ICP-332)\, phase 3\, Atopic Dermatitis.\nStudy: IC
 P-332 in Subjects With Moderate to Severe Atopic Dermatitis\nEstimated pri
 mary completion: 25 November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/soficitinib-icp-332#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06775860
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298395-1361@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ENV-294: Phase 2 readout est. (NCT07298395)
DESCRIPTION:ENV-294\, phase 2\, Atopic Dermatitis.\nStudy: Study of ENV-294
  in Adults With Moderate-to-Severe Atopic Dermatitis\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/env-294#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07298395
URL:https://assetmemo.bio/drug/env-294#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07173478-1444@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Moizerto / Adquey (difamilast): Phase 3 readout est. (NCT07173478)
DESCRIPTION:Moizerto / Adquey (difamilast)\, phase 3\, Atopic Dermatitis.\n
 Study: A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam
  to the Vehicle in Adult Patients With Atopic Dermatitis\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/difamilast#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07173478
URL:https://assetmemo.bio/drug/difamilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06094179-1438@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vedastotug: Phase 1/2 readout est. (NCT06094179)
DESCRIPTION:Vedastotug\, phase 1/2\, Atopic Dermatitis.\nStudy: Evaluate th
 e Safety\, Tolerability of BAT6026\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vedastotug#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0609
 4179
URL:https://assetmemo.bio/drug/vedastotug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701331-12@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06701331)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: Sa
 fety and Efficacy of Upadacitinib in Combination With Topical Corticostero
 ids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate
  to Severe Atopic Dermatitis\nEstimated primary completion: January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06701331
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162896-1346@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Eucrisa (crisaborole): Phase 3 readout est. (NCT07162896)
DESCRIPTION:Eucrisa (crisaborole)\, phase 3\, Atopic Dermatitis.\nStudy: Cr
 isaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atop
 ic Dermatitis\nEstimated primary completion: January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/crisaborole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07162896
URL:https://assetmemo.bio/drug/crisaborole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465120-1339@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:CMS-D001: Phase 2 readout est. (NCT07465120)
DESCRIPTION:CMS-D001\, phase 2\, Atopic Dermatitis.\nStudy: A Multicenter\,
  Randomized\, Double-Blind\, Placebo-Controlled\, Phase Ⅱ Clinical Study
  to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Mo
 derate to Severe Atopic Dermatitis\nEstimated primary completion: 31 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cms-d001#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746512
 0
URL:https://assetmemo.bio/drug/cms-d001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524635-103@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06524635)
DESCRIPTION:lutikizumab\, phase 2\, Atopic Dermatitis.\nStudy: A Study to A
 ssess Molecular Changes in Adult Participants With Moderate to Severe Hidr
 adenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receivin
 g Subcutaneous Injections of Lutikizumab\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lutikizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06524635
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106372-1335@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:stapokibart: Phase 3 readout est. (NCT07106372)
DESCRIPTION:stapokibart\, phase 3\, Atopic Dermatitis.\nStudy: A Study of S
 tapokibatrt in Children Subjects With Atopic Dermatitis\nEstimated primary
  completion: February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07106372
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184645-1444@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Moizerto / Adquey (difamilast): Phase 3 readout est. (NCT07184645)
DESCRIPTION:Moizerto / Adquey (difamilast)\, phase 3\, Atopic Dermatitis.\n
 Study: A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atop
 ic Dermatitis\nEstimated primary completion: February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/difamilast#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07184645
URL:https://assetmemo.bio/drug/difamilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598383-1511@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:VC005: Phase 2 readout est. (NCT07598383)
DESCRIPTION:VC005\, phase 2\, Atopic Dermatitis.\nStudy: A Multicenter\, Ra
 ndomized\, Double-blind\, Vehicle Controlled Phase II Clinical Study to Ev
 aluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to
  Moderate Atopic Dermatitis\nEstimated primary completion: 22 February 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/vc005#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07598383
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105488-1310@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:BFB759: Phase 2 readout est. (NCT07105488)
DESCRIPTION:BFB759\, phase 2\, Atopic Dermatitis.\nStudy: A Study Evaluatin
 g BFB759 in Moderate to Severe Atopic Dermatitis\nEstimated primary comple
 tion: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bfb759#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07105488
URL:https://assetmemo.bio/drug/bfb759#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880276-1468@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:QLM3003: Phase 3 readout est. (NCT06880276)
DESCRIPTION:QLM3003\, phase 3\, Atopic Dermatitis.\nStudy: Efficacy and Saf
 ety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic
  Dermatitis\nEstimated primary completion: March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/qlm3003#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06880276
URL:https://assetmemo.bio/drug/qlm3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07386743-1376@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:GS101: Phase 3 readout est. (NCT07386743)
DESCRIPTION:GS101\, phase 3\, Atopic Dermatitis.\nStudy: A Phase III Study 
 of GS101 Injection to Dupixent®\nEstimated primary completion: April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/gs101#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07386743
URL:https://assetmemo.bio/drug/gs101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07445919-1493@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:SM17: Phase 2 readout est. (NCT07445919)
DESCRIPTION:SM17\, phase 2\, Atopic Dermatitis.\nStudy: A Clinical Study to
  Evaluate SM17 for Atopic Dermatitis\nEstimated primary completion: 25 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sm17#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07445919
URL:https://assetmemo.bio/drug/sm17#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526182-1423@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT06526182)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-t
 o-Severe Atopic Dermatitis\nEstimated primary completion: 25 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06526182
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06718101-103@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06718101)
DESCRIPTION:lutikizumab\, phase 2\, Atopic Dermatitis.\nStudy: A Study to E
 valuate the Effectiveness and Safety of Treatments\, Either Alone or in Co
 mbination\, for the Treatment of Moderate to Severe Atopic Dermatitis\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06718101
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884891-1467@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:QL2108: Phase 3 readout est. (NCT06884891)
DESCRIPTION:QL2108\, phase 3\, Atopic Dermatitis.\nStudy: A Phase Ⅲ Compa
 rative Study of QL2108 to Dupixent®\nEstimated primary completion: May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ql2108#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06884891
URL:https://assetmemo.bio/drug/ql2108#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220577-1372@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:GIA632: Phase 2 readout est. (NCT07220577)
DESCRIPTION:GIA632\, phase 2\, Atopic Dermatitis.\nStudy: Phase 2a Study to
  Assess the Efficacy\,Safety and Tolerability of GIA632 in Adult Participa
 nts With Moderate to Severe Atopic Dermatitis\nEstimated primary completio
 n: 17 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gia63
 2#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 220577
URL:https://assetmemo.bio/drug/gia632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277660-1380@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:galvokimig: Phase 2 readout est. (NCT07277660)
DESCRIPTION:galvokimig\, phase 2\, Atopic Dermatitis.\nStudy: A Dose-rangin
 g Study to Evaluate the Efficacy\, Safety\, Pharmacokinetics\, and Pharmac
 odynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
 \nEstimated primary completion: 17 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/galvokimig#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07277660
URL:https://assetmemo.bio/drug/galvokimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06397911-1367@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:FB825: Phase 2 readout est. (NCT06397911)
DESCRIPTION:FB825\, phase 2\, Atopic Dermatitis.\nStudy: Evaluate Efficacy 
 and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-t
 o-Severe Atopic Dermatitis\nEstimated primary completion: 31 May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fb825#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06397911
URL:https://assetmemo.bio/drug/fb825#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217015-1407@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:KT-621: Phase 2 readout est. (NCT07217015)
DESCRIPTION:KT-621\, phase 2\, Atopic Dermatitis.\nStudy: A Study of KT-621
  Administered Orally to Participants With Moderate to Severe Atopic Dermat
 itis\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/kt-621#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07217015
URL:https://assetmemo.bio/drug/kt-621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321951-1489@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-1819: Phase 2 readout est. (NCT07321951)
DESCRIPTION:SHR-1819\, phase 2\, Atopic Dermatitis.\nStudy: A Study of SHR-
 1819 in Patients With Moderate-to-severe Atopic Dermatitis\nEstimated prim
 ary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/shr-1819#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07321951
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441395-1499@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:soquelitinib: Phase 2 readout est. (NCT07441395)
DESCRIPTION:soquelitinib\, phase 2\, Atopic Dermatitis.\nStudy: Study to Ev
 aluate Soquelitinib in Participants With Moderate to Severe AD\nEstimated 
 primary completion: June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/soquelitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07441395
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629778-1383@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HL-300: Phase 1/2 readout est. (NCT07629778)
DESCRIPTION:HL-300\, phase 1/2\, Atopic Dermatitis.\nStudy: HL-300 Ointment
  in Patients With Mild-to-Moderate Atopic Dermatitis\nEstimated primary co
 mpletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/hl-300#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07629778
URL:https://assetmemo.bio/drug/hl-300#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767540-1280@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Manfidokimab: Phase 3 readout est. (NCT06767540)
DESCRIPTION:Manfidokimab\, phase 3\, Atopic Dermatitis.\nStudy: A Clinical 
 Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis\nE
 stimated primary completion: 10 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/manfidokimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06767540
URL:https://assetmemo.bio/drug/manfidokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265479-1783@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tapinarof: Phase 3 readout est. (NCT07265479)
DESCRIPTION:Tapinarof\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Inv
 estigate Safety and Efficacy of Tapinarof Cream\, 1% in Participants Ages 
 3 Months to < 24 Months With Atopic Dermatitis\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tapi
 narof#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07265479
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06723080-1511@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:VC005: Phase 3 readout est. (NCT06723080)
DESCRIPTION:VC005\, phase 3\, Atopic Dermatitis.\nStudy: Phase III Clinical
  Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic D
 ermatitis\nEstimated primary completion: 30 August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/vc005#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06723080
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07344051-1469@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:QLS12010: Phase 2 readout est. (NCT07344051)
DESCRIPTION:QLS12010\, phase 2\, Atopic Dermatitis.\nStudy: A Phase II Stud
 y of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis
 \nEstimated primary completion: September 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/qls12010#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07344051
URL:https://assetmemo.bio/drug/qls12010#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767253-1275@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SSGJ-611: Phase 3 readout est. (NCT07767253)
DESCRIPTION:SSGJ-611\, phase 3\, Atopic Dermatitis.\nStudy: Evaluation of 6
 11 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)\nEsti
 mated primary completion: September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ssgj-611#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07767253
URL:https://assetmemo.bio/drug/ssgj-611#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06487000-1357@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Mosedipimod: Phase 2 readout est. (NCT06487000)
DESCRIPTION:Mosedipimod\, phase 2\, Atopic Dermatitis.\nStudy: Determine th
 e Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to
  Severe Atopic Dermatitis\nEstimated primary completion: October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/mosedipimod#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06487000
URL:https://assetmemo.bio/drug/mosedipimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762833-1524@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Nemluvio (nemolizumab): Phase 3 readout est. (NCT07762833)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 3\, Atopic Dermatitis.\nStudy: R
 andomized\, Double-blind\, Placebo-controlled Study of Nemolizumab in Chin
 ese Subjects With Moderate-to-severe Atopic Dermatitis\nEstimated primary 
 completion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07762833
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599813-1343@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:camoteskimab: Phase 2 readout est. (NCT07599813)
DESCRIPTION:camoteskimab\, phase 2\, Atopic Dermatitis.\nStudy: A Phase 2b 
 Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Ato
 pic Dermatitis\nEstimated primary completion: 31 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/camoteskimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07599813
URL:https://assetmemo.bio/drug/camoteskimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502222-1281@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:AK139: Phase 2 readout est. (NCT07502222)
DESCRIPTION:AK139\, phase 2\, Atopic Dermatitis.\nStudy: A Study to Evaluat
 e the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Ato
 pic Dermatitis\nEstimated primary completion: November 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ak139#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07502222
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309055-1489@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SHR-1819: Phase 3 readout est. (NCT07309055)
DESCRIPTION:SHR-1819\, phase 3\, Atopic Dermatitis.\nStudy: A Study of SHR-
 1819 Injection in Adolescents With Severe Atopic Dermatitis\nEstimated pri
 mary completion: November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-1819#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07309055
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678645-12@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT07678645)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2\, Atopic Dermatitis.\nStudy: Th
 e Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cho
 langitis and Atopic Dermatitis With Moderate to Severe Itching\nEstimated 
 primary completion: 30 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07678645
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230483-1337@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:CM512: Phase 2 readout est. (NCT07230483)
DESCRIPTION:CM512\, phase 2\, Atopic Dermatitis.\nStudy: A Long-term Safety
  and Efficacy Study Evaluating CM512 in Atopic Dermatitis.\nEstimated prim
 ary completion: December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cm512#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07230483
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643766-1361@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ENV-294: Phase 2 readout est. (NCT07643766)
DESCRIPTION:ENV-294\, phase 2\, Atopic Dermatitis.\nStudy: A Phase 2b Dose-
 Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults Wit
 h Moderate-to-Severe Atopic Dermatitis\nEstimated primary completion: Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/env-294#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076437
 66
URL:https://assetmemo.bio/drug/env-294#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037901-1394@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olevaprubart: Phase 2 readout est. (NCT07037901)
DESCRIPTION:Olevaprubart\, phase 2\, Atopic Dermatitis.\nStudy: A Study to 
 Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Mod
 erate-to-Severe Atopic Dermatitis\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/olevaprubart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070379
 01
URL:https://assetmemo.bio/drug/olevaprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735483-1423@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT05735483)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650
 150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe 
 Atopic Dermatitis\nEstimated primary completion: December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05735483
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193589-51@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:ZL-82: Phase 2 readout est. (NCT07193589)
DESCRIPTION:ZL-82\, phase 2\, Atopic Dermatitis.\nStudy: A Phase II Clinica
 l Study Evaluating of ZL-82 Tablets in Atopic Dermatitis\nEstimated primar
 y completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zl-82#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07193589
URL:https://assetmemo.bio/drug/zl-82#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895615-1416@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:LT-002-158: Phase 2 readout est. (NCT07895615)
DESCRIPTION:LT-002-158\, phase 2\, Atopic Dermatitis.\nStudy: Phase II Clin
 ical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Ad
 ult Patients With Moderate-to-Severe Atopic Dermatitis\nEstimated primary 
 completion: January 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lt-002-158#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07895615
URL:https://assetmemo.bio/drug/lt-002-158#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873801-1423@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT07873801)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic
  Dermatitis\nEstimated primary completion: February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07873801
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216027-1457@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:PF-08049820: Phase 2 readout est. (NCT07216027)
DESCRIPTION:PF-08049820\, phase 2\, Atopic Dermatitis.\nStudy: A Study to L
 earn About Study Medicine Called PF-08049820 in People With Eczema\nEstima
 ted primary completion: 2 February 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pf-08049820#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07216027
URL:https://assetmemo.bio/drug/pf-08049820#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931990-1416@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:LT-002-158: Phase 1/2 readout est. (NCT06931990)
DESCRIPTION:LT-002-158\, phase 1/2\, Atopic Dermatitis.\nStudy: A Study to 
 Explore the Safety\, Tolerability\, Efficacy\, and Pharmacokinetics of LT-
 002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis\nEstimate
 d primary completion: 17 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lt-002-158#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06931990
URL:https://assetmemo.bio/drug/lt-002-158#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734415-1394@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olevaprubart: Phase 2 readout est. (NCT07734415)
DESCRIPTION:Olevaprubart\, phase 2\, Atopic Dermatitis.\nStudy: Long-term S
 afety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-
 Severe Atopic Dermatitis\nEstimated primary completion: March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olevaprubart#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07734415
URL:https://assetmemo.bio/drug/olevaprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765888-1455@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07765888)
DESCRIPTION:tilrekimig\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Le
 arn About the Study Medicine Called Tilrekimig in People With Moderate-to-
 Severe Eczema\nEstimated primary completion: 10 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07765888
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07370909-1418@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:LW402: Phase 3 readout est. (NCT07370909)
DESCRIPTION:LW402\, phase 3\, Atopic Dermatitis.\nStudy: Evaluation of the 
 Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients Wi
 th Moderate-to-Severe Atopic Dermatitis\nEstimated primary completion: 31 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lw402#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0737090
 9
URL:https://assetmemo.bio/drug/lw402#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916480-1479@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Roflumilast (Zoryve): Phase 3 readout est. (NCT07916480)
DESCRIPTION:Roflumilast (Zoryve)\, phase 3\, Atopic Dermatitis.\nStudy: Rof
 lumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis\nEstimated pr
 imary completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/roflumilast-zoryve#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07916480
URL:https://assetmemo.bio/drug/roflumilast-zoryve#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690371-70@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:rezpegaldesleukin: Phase 3 readout est. (NCT07690371)
DESCRIPTION:rezpegaldesleukin\, phase 3\, Atopic Dermatitis.\nStudy: A Phas
 e 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age
  With Moderate-to-Severe Atopic Dermatitis\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezpegaldes
 leukin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07690371
URL:https://assetmemo.bio/drug/rezpegaldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919899-1356@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280502
DTEND;VALUE=DATE:20280503
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07919899)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Atopic Dermatitis.\nStudy: Pha
 rmacokinetics\, Immunogenicity and Safety of Subcutaneous Dupilumab and Be
 rahyaluronidase Alfa (ALT-B4) Coformulation\nEstimated primary completion:
  2 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupiluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 919899
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592585-1511@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:VC005: Phase 3 readout est. (NCT07592585)
DESCRIPTION:VC005\, phase 3\, Atopic Dermatitis.\nStudy: Phase III Clinical
  Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Derm
 atitis\nEstimated primary completion: 30 May 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/vc005#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07592585
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711418-70@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:rezpegaldesleukin: Phase 3 readout est. (NCT07711418)
DESCRIPTION:rezpegaldesleukin\, phase 3\, Atopic Dermatitis.\nStudy: A Phas
 e 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age
  With Moderate-to-Severe Atopic Dermatitis\nEstimated primary completion: 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezpegalde
 sleukin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07711418
URL:https://assetmemo.bio/drug/rezpegaldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660835-1524@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280715
DTEND;VALUE=DATE:20280716
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07660835)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2\, Atopic Dermatitis.\nStudy: P
 harmacokinetics\, Safety and Efficacy of Nemolizumab in Participants Aged 
 6 to 23 Months With Moderate-to Severe Atopic Dermatitis\nEstimated primar
 y completion: 15 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07660835
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783425-1455@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280908
DTEND;VALUE=DATE:20280909
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07783425)
DESCRIPTION:tilrekimig\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Le
 arn About the Study Medicine Called Tilrekimig in People With Moderate-to 
 Severe Eczema\nEstimated primary completion: 8 September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07783425
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947993-1371@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20281127
DTEND;VALUE=DATE:20281128
SUMMARY:GHZ339: Phase 2 readout est. (NCT06947993)
DESCRIPTION:GHZ339\, phase 2\, Atopic Dermatitis.\nStudy: Platform Study to
  Evaluate the Efficacy and Safety of Investigational Compound(s) in Patien
 ts With Moderate to Severe Atopic Dermatitis\nEstimated primary completion
 : 27 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 hz339#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06947993
URL:https://assetmemo.bio/drug/ghz339#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242638-1302@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Cibinqo (abrocitinib): Phase 2 readout est. (NCT07242638)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 2\, Atopic Dermatitis.\nStudy: Tr
 eatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Indiv
 iduals With Down Syndrome\nEstimated primary completion: 23 February 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/abrocitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07242638
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823595-1302@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20290410
DTEND;VALUE=DATE:20290411
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT07823595)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3\, Atopic Dermatitis.\nStudy: Ab
 rocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Year
 s of Age\nEstimated primary completion: 10 April 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/abrocitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07823595
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377838-1277@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:ADSTEM: Phase 3 readout est. (NCT07377838)
DESCRIPTION:ADSTEM\, phase 3\, Atopic Dermatitis.\nStudy: Study of ADSTEM I
 njection for Patients With Moderate to Severe Subacute and Chronic Atopic 
 Dermatitis\nEstimated primary completion: September 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adstem#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07377838
URL:https://assetmemo.bio/drug/adstem#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06461897-12@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06461897)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Study to Assess Adverse Events and Change in Disease Activity Comparing Or
 al Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 
 12 Years of Age With Moderate to Severe Atopic Dermatitis\nEstimated prima
 ry completion: November 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06461897
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003425-1285@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Zumilokibart: Phase 2 readout est. (NCT07003425)
DESCRIPTION:Zumilokibart\, phase 2\, Atopic Dermatitis.\nStudy: A Long-term
  Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis\nEstimat
 ed primary completion: December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zumilokibart#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07003425
URL:https://assetmemo.bio/drug/zumilokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807281-1302@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20320222
DTEND;VALUE=DATE:20320223
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT06807281)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Year
 s and Older With Moderate to Severe Eczema\nEstimated primary completion: 
 22 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abr
 ocitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06807281
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223697-20@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:afimkibart: Phase 2 readout est. (NCT07223697)
DESCRIPTION:afimkibart\, phase 2\, Atopic Dermatitis.\nStudy: A Long Term E
 xtension Study to Evaluate the Safety and Efficacy of Afimkibart (RO779012
 1) in Participants With Atopic Dermatitis\nEstimated primary completion: 1
  March 2033. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/afimkiba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7223697
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
